EUVIMEDEUVIMED entdecken
Crossref

Survival Outcomes and Treatment Modalities in Aplastic Anaemia Patients: A Six-Year Retrospective Study at Muhimbili National Hospital, Tanzania

Gladys Nicholas Kaaya, Magdalena Lyimo, Clara Chamba, Ahlam Nasser Ahlam Nasser, William Mawalla, Rebbecca Mwakichako, Michelle Munroe, Johnson Mshiu, Eunice Shija, Koga Luhulla, Mwashungi Ally

East African Health Research Journal · 04.11.2026 · 10 (2)

DOI: 10.24248/eahrj.v10i2.340 ↗

Kurz gefasst

Fachartikel in der Zeitschrift East African Health Research Journal, online erschienen am 04.11.2026. Verfasst von Gladys Nicholas Kaaya und 10 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Aplastic anaemia (AA) is a rare bone marrow failure syndrome characterised by pancytopenia and hypocellular marrow, often resulting from immune-mediated hematopoietic stem cell destruction. Survival data for AA in Tanzania is limited. This study assessed the survival outcomes of AA patients based on available treatment regimens at Muhimbili National Hospital (MNH).

Methods

A retrospective cohort study included all AA patients identified and treated at MNH between January 2018 and December 2023. Clinical and laboratory data, along with socio-demographic information, were extracted from patients’ records. Descriptive statistics of patient characteristics, Kaplan-Meier curves estimated survival outcomes, and the Cox regression model assessed factors associated with mortality risk.

Results

Among 577 patients with pancytopenia, 156 (27%) had acquired idiopathic aplastic anaemia. The median age at diagnosis was 23 years. Majority of the patients had severe AA (49.4%) and very severe AA (36.5%). Treatment regimens included cyclosporine A (59.0%), supportive care alone (21.8%), intensive immunosuppressive therapy (14.1%), and other treatments (4.5%). Only 3 (1.9%) patients underwent allogeneic hematopoietic stem cell transplant abroad. The Kaplan–Meier estimate of overall survival was 27.6%, with a median survival time of 158 days from diagnosis. Supportive care alone and cyclosporine A plus supportive care were associated with higher mortality compared to intensive immunosuppressive therapy.

Conclusion

Patients receiving intensive immunosuppressive therapy demonstrated the most favourable survival outcomes; however, these findings should be interpreted cautiously given the observational design. Expanding access to allogeneic hematopoietic stem cell transplantation and intensive immunosuppressive therapy, alongside early detection and timely referral, is crucial for improving survival of aplastic anaemia patients in Tanzania.

Zitieren

APA

Kaaya, G. N., Lyimo, M., Chamba, C., Nasser, A. N. A., Mawalla, W., Mwakichako, R., Munroe, M., Mshiu, J., Shija, E., Luhulla, K., & Ally, M. (2026). Survival Outcomes and Treatment Modalities in Aplastic Anaemia Patients: A Six-Year Retrospective Study at Muhimbili National Hospital, Tanzania. East African Health Research Journal, 10(2). https://doi.org/10.24248/eahrj.v10i2.340

Vancouver

Kaaya GN, Lyimo M, Chamba C, Nasser ANA, Mawalla W, Mwakichako R, et al. Survival Outcomes and Treatment Modalities in Aplastic Anaemia Patients: A Six-Year Retrospective Study at Muhimbili National Hospital, Tanzania. East African Health Research Journal. 2026;10(2). doi:10.24248/eahrj.v10i2.340

BibTeX
@article{Kaaya2026,
  author = {Kaaya, Gladys Nicholas and Lyimo, Magdalena and Chamba, Clara and Nasser, Ahlam Nasser Ahlam and Mawalla, William and Mwakichako, Rebbecca and Munroe, Michelle and Mshiu, Johnson and Shija, Eunice and Luhulla, Koga and Ally, Mwashungi},
  title = {Survival Outcomes and Treatment Modalities in Aplastic Anaemia Patients: A Six-Year Retrospective Study at Muhimbili National Hospital, Tanzania},
  journal = {East African Health Research Journal},
  year = {2026},
  volume = {10},
  number = {2},
  doi = {10.24248/eahrj.v10i2.340}
}
Kostenlos starten →